CN Mobile Logo

Search form


Zeneca Files NDA for Arimidex

Zeneca Files NDA for Arimidex

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application (NDA) for the use of Arimidex (anastrozole) tablets for the treatment of advanced breast cancer in postmenopausal women who have progressed following therapy with tamoxifen (Nolvadex).

Arimidex, a nonsteroidal compound, is one of the first of a new class of selective oral aromatase inhibitors, designed to reduce the production of estrogen. The NDA is based on randomized, controlled trials involving 764 women with advanced breast cancer, the company said.

By clicking Accept, you agree to become a member of the UBM Medica Community.